Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Point Biopharma Global Inc.
Headquarters: Toronto, ON, Canada
Website: N/A
Year Founded: 2019
Status: Acquired
BioCentury | Feb 11, 2025
Deals
After stumbles along winding path, Acelyrin merges with Alumis: Deals Report
Plus: Pair of cash-rich biotechs agree to combine, and Australian radiopharma company Advancell follows venture round by expanding Lilly relationship
BioCentury | Feb 7, 2025
Product Development
The radiopharma landscape takes shape in neuroendocrine tumors
Itm and Perspective’s readouts are the latest clinical advances in GEP-NETs, the first indication to put radioligand therapies on the map
BioCentury | Jul 23, 2024
Product Development
Lead-212’s leading players
Decisions about manufacturing and distribution could be make-or-break for drug developers producing their own lead-212
BioCentury | Jul 22, 2024
Product Development
Battle of the alphas: lead-212 picks up speed in radiopharma
The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale
BioCentury | Jul 1, 2024
Deals
Deals Report: Eisai regains ADC’s rights from BMS; Lilly’s latest radiopharma play
Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira
BioCentury | May 2, 2024
Deals
Novartis gains α-emitter, radioligand platform via $1B Mariana takeout
Largest upfront M&A payment for a preclinical biotech in three years
BioCentury | Mar 21, 2024
Data Byte
Radiopharmaceuticals could soon get their first blockbuster
Pluvicto’s steep launch appears on track to surpass $1B in sales this year
BioCentury | Mar 19, 2024
Deals
AZ deepens radiopharma commitment via $2B Fusion takeout
Deal brings more momentum for α-emitters, with Fusion’s lead program contrasting Novartis’ β-emitting Pluvicto
BioCentury | Dec 19, 2023
Data Byte
Comparing Point and Novartis radiopharmaceuticals readouts
The manufacturing-focused radiopharma met its primary endpoint but fell short of Novartis on rPFS; both companies face the same OS challenge
BioCentury | Dec 1, 2023
Product Development
Radiopharmaceuticals’ multi-dimensional next wave
Target, ligand and radioisotope choices fuel the growing field
Items per page:
1 - 10 of 19